Barinthus Biotherapeutics receives notice of non-compliance with Nasdaq listing standards

Barinthus Biotherapeutics has disclosed receipt of a deficiency notice from Nasdaq regarding failure to satisfy continued listing requirements. The filing indicates potential delisting risks, though the company's specific remediation plan or the nature of the deficiency remains to be detailed in subsequent disclosures.